[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Jung CK, Lee JH, Lee CM, Won JJ, Baek YH, Lee JM, Lee SA: [A case of primary sigmoid colon mucosa-associated lymphoid tissue lymphoma]. Korean J Gastroenterol; 2009 Aug;54(2):126-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary sigmoid colon mucosa-associated lymphoid tissue lymphoma].
  • The gastrointestinal (GI) tract is the most frequently involved site of mucosa-associated lymphoid tissue (MALT) lymphoma.
  • However, MALT lymphoma of the large intestine is rare.
  • A 72-year-old man with low abdominal pain was diagnosed as a sigmoid MALT lymphoma, which was noted as an obstructing mass in a colonoscopic examination.
  • A left hemicolectomy was performed, and the patient has had no recurrence postoperatively without any chemotherapy.
  • [MeSH-major] Colon, Sigmoid / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696541.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


2. Ikuta K, Fujiya M, Ueno N, Hosoki T, Moriichi K, Honda M, Torimoto Y, Yamochi T, Ota H, Kohgo Y: Atypical mucosa-associated lymphoid tissue lymphoma in the transverse colon associated with macroglobulinemia. Intern Med; 2010;49(7):677-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical mucosa-associated lymphoid tissue lymphoma in the transverse colon associated with macroglobulinemia.
  • We herein present a quite atypical case of primary gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma in the transverse colon.
  • Computed tomography and endoscopic ultrasonography revealed diffuse thickening of the wall, and colonoscopy showed a white-colored mucosa with reduced superficial vessels in the entire transverse colon.
  • The lesion was diagnosed as MALT lymphoma by pathological examination of the biopsied specimen.
  • Secondary macroglobulinemia of IgM-kappa type was also found in the present case.
  • After chemotherapy and radiation, the lesions in the transverse colon improved and the patient has been in good condition without any evidence of recurrence for more than 1 year.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Waldenstrom Macroglobulinemia / diagnosis
  • [MeSH-minor] Colon, Transverse / pathology. Colon, Transverse / surgery. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371958.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Gezen C, Kement M, Oncel M, Tuncay E, Sahlepci T, Alkan S: Mucosa associated lymphoid tissue lymphoma of the colon: a case report. Cases J; 2009;2:9316

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa associated lymphoid tissue lymphoma of the colon: a case report.
  • The histological and immunochemical evaluation showed atypical lymphoid cell proliferation and lymphoepithelial lesions on the colonic mucosa, staining with CD20 (CD20 x 100).
  • After the diagnosis had been confirmed as low grade mucosa associated lymphoid tissue lymphoma.
  • Abdominal computed tomography revealed polypoid lesions throughout the colon and multiple milimetrics lymphadenopathies in the mesentery.
  • The patient was treated with a chemotherapy regimen.
  • During the follow-up, colonoscopic examination and blind biopsies were repeated in every 6 months, revealed endoscopically and pathologically normal mucosa each time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Histopathology. 1994 Apr;24(4):357-62 [8045524.001]
  • [Cites] Gut. 2000 Jan;46(1):133-5 [10601069.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):36-42 [12499431.001]
  • [Cites] Yonsei Med J. 2003 Oct 30;44(5):757-70 [14584090.001]
  • [Cites] Australas Radiol. 2005 Oct;49(5):353-64 [16174173.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Lab Invest. 1994 Apr;70(4):572-8 [8176897.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2387-9 [11007252.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):448-52 [11289295.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1003-5 [12845967.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • (PMID = 20062639.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803979
  •  go-up   go-down


Advertisement
4. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the colon.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Most of the previous publications used old pathologic classifications and old diagnostic and treatment approaches.
  • OBJECTIVE: To examine the clinical presentation, pathologic classification, treatment and outcome of patients with NHL of the colon.
  • METHODS: A retrospective study was performed of all patients with NHL and involvement of the colon in two medical centers.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • CONCLUSIONS: Most colonic lymphomas are aggressive B cell lymphomas.
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


5. Raderer M, Wöhrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B, Zielinski CC: Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol; 2005 Nov 20;23(33):8442-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma.
  • PURPOSE: Various chemotherapeutic regimens have been applied for treatment of mucosa-associated lymphoid tissue (MALT) lymphoma, but no standard regimen has been identified to date.
  • In view of the activity of oxaliplatin (L-OHP) in various types of lymphoma, we performed a phase II study to evaluate the activity of L-OHP for treatment of MALT lymphoma.
  • PATIENTS AND METHODS: A total of 16 patients with MALT lymphoma of various sites of origin (four of the ocular adnexa, five of the salivary glands, three of the stomach, two of the lung, and one of the colon and the breast) were administered L-OHP at a dose of 130 mg/m2 infused during 2 hours every 3 weeks.
  • Restaging was performed every two cycles; treatment was continued until complete remission (CR) or for a maximum of six cycles in responders.
  • Fifteen patients responded to chemotherapy, with nine achieving CR (56%), six (37.5%) achieving partial response, and one achieving stable disease; the median time to response was 4 months (range; 2 to 4 months).
  • CONCLUSION: These data suggest L-OHP is a highly active agent for treatment of MALT lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Austria / epidemiology. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293875.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


6. Quayle FJ, Lowney JK: Colorectal lymphoma. Clin Colon Rectal Surg; 2006 May;19(2):49-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal lymphoma.
  • Lymphoma involving the colon and rectum is rare and can occur either as primary colorectal lymphoma or as a manifestation of systemic disease.
  • Most patients with primary colorectal lymphoma present with abdominal pain, and obstruction is unusual.
  • However, recent reports suggest increased rates of mucosa-associated lymphoid tissue (MALT) lymphoma and mantle cell lymphoma (MCL) with increased surveillance.1 Most patients with colorectal lymphoma undergo surgery, but multiagent chemotherapy remains the mainstay of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Br J Cancer. 1989 Feb;59(2):276-82 [2930692.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1301-8 [4045524.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):291-7 [8071513.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Ann Surg. 1980 May;191(5):593-8 [6989331.001]
  • [Cites] Lancet. 1975 Feb 1;1(7901):248-50 [46388.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] J Surg Oncol. 2002 Jun;80(2):111-5 [12173380.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):586-91 [12548600.001]
  • [Cites] J Gastroenterol. 2003;38(4):376-84 [12743779.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] Radiology. 2004 May;231(2):305-32 [15044750.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):257-62 [10962456.001]
  • (PMID = 20011310.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780105
  • [Keywords] NOTNLM ; Lymphoma / immunosuppression
  •  go-up   go-down


7. Matsuo S, Mizuta Y, Hayashi T, Susumu S, Tsutsumi R, Azuma T, Yamaguchi S: Mucosa-associated lymphoid tissue lymphoma of the transverse colon: a case report. World J Gastroenterol; 2006 Sep 14;12(34):5573-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue lymphoma of the transverse colon: a case report.
  • We herein present a case of a 75-year-old female with mucosa-associated lymphoid tissue (MALT) lymphoma of the transverse colon with the stage IE (Ann Arbor classification).
  • Colonoscopy revealed the tumor's appearance as a IIa plus II c-like early colon cancer as defined according to the macroscopic classification of the Japanese Research Society for Cancer of Colon, Rectum and Anus, measuring less than 2 cm in diameter.
  • Histologically, the tumor was diagnosed as MALT lymphoma because of the presence of lymphoepithelial lesions consisting of diffuse proliferation of atypical lymphocytes and glandular destruction.
  • The patient first underwent H pylori eradication therapy with Lansap.
  • The operative procedure included a partial colectomy with dissection of the paracolic lymph nodes.
  • The tumor measured 45 mm multiply 30 mm in diameter and histological examination showed that the lymphoma cells had infiltrated the muscle layer of the colon without nodal involvement.
  • The patient has had no recurrence postoperatively without any chemotherapy.
  • [MeSH-major] Colonic Neoplasms / microbiology. Colonic Neoplasms / surgery. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / surgery
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Colon, Transverse / microbiology. Colon, Transverse / pathology. Colon, Transverse / surgery. Disease Progression. Drug Resistance, Microbial. Female. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1003-5 [12845967.001]
  • [Cites] Scand J Gastroenterol Suppl. 1988;142:44-9 [3166533.001]
  • [Cites] J Clin Pathol. 1989 Dec;42(12):1269-71 [2613920.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Histopathology. 1994 Apr;24(4):357-62 [8045524.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1624-30 [9193362.001]
  • [Cites] Lancet. 1997 Jul 12;350(9071):115-6 [9228971.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5 [9308704.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S8-12 [9894466.001]
  • [Cites] Ann Intern Med. 1999 Jul 20;131(2):88-95 [10419446.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):637-45 [10442184.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):514-5 [10465640.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2352-4 [10521996.001]
  • [Cites] J Korean Med Sci. 2005 Apr;20(2):325-8 [15832010.001]
  • [Cites] J Gastroenterol. 2005 Aug;40(8):843-7 [16143891.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1370-5 [16549831.001]
  • [Cites] Gut. 2000 Jan;46(1):133-5 [10601069.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Gastroenterology. 2000 May;118(5):821-8 [10784580.001]
  • [Cites] Gastrointest Endosc. 2000 Dec;52(6):802-4 [11115928.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • [Cites] Gut. 2001 Oct;49(4):584-7 [11559658.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 1999 Apr;9(2):156-9 [11757546.001]
  • [Cites] Gastrointest Endosc. 2002 Feb;55(2):238-9 [11818929.001]
  • [Cites] Endoscopy. 2002 Apr;34(4):343-6 [11932795.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1267-70 [12352248.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • (PMID = 17007004.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC4088249
  •  go-up   go-down


8. Raderer M, Pfeffel F, Pohl G, Mannhalter C, Valencak J, Chott A: Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Gut; 2000 Jan;46(1):133-5
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori.
  • BACKGROUND: Lymphoma of the mucosa associated lymphoid tissue (MALT) arising in the stomach has been shown to be related to Helicobacter pylori infection, and total regression of gastric lymphoma after successful eradication of H pylori has consistently been reported.
  • MALT-type lymphoma at other localisations, however, has to our knowledge not been linked to H pylori, and eradication of the bacteria has not been studied for management of such lymphomas.
  • PATIENT/METHOD: A 67 year old man was diagnosed with MALT-type lymphoma simultaneously involving the stomach and the colon descendens.
  • In addition to the presence of MALT-type lymphoma, H pylori associated chronic gastritis was diagnosed, and treatment with clarithromycin, metronidazole, and omeprazole was initiated, resulting in its successful eradication.
  • RESULTS: Follow up performed four months later showed regression of the colonic manifestation, whereas the gastric lymphoma did not respond to antibiotic treatment, as assessed by regular follow up for 14 months, in spite of its restriction to mucosa and submucosa.
  • The patient was therefore treated with oral cyclophosphamide (100 mg a day) resulting in partial remission after seven months of continuous treatment.
  • Because of the presence of residual lymphoma, additional irradiation was performed, which led to complete remission of the gastric lymphoma.
  • The patient remains in complete remission 40 months after diagnosis and 26 months after initiation of treatment.
  • CONCLUSION: In the case of concurrent gastric and intestinal low grade MALT-type lymphoma, H pylori eradication may cause regression of the intestinal lesion.
  • [MeSH-major] Colonic Neoplasms / microbiology. Helicobacter Infections / complications. Helicobacter pylori. Lymphoma, B-Cell, Marginal Zone / microbiology
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Anti-Ulcer Agents / therapeutic use. Clarithromycin / therapeutic use. Drug Therapy, Combination. Follow-Up Studies. Humans. Male. Metronidazole / therapeutic use. Omeprazole / therapeutic use

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gut. 2001 Feb;48(2):283 [11211858.001]
  • (PMID = 10601069.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 140QMO216E / Metronidazole; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  • [Other-IDs] NLM/ PMC1727770
  •  go-up   go-down


9. Yoshino T, Ichimura K, Mannami T, Takase S, Ohara N, Okada H, Akagi T: Multiple organ mucosa-associated lymphoid tissue lymphomas often involve the intestine. Cancer; 2001 Jan 15;91(2):346-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple organ mucosa-associated lymphoid tissue lymphomas often involve the intestine.
  • BACKGROUND: Low grade mucosa-associated lymphoid tissue (MALT) lymphomas usually are confined to single extranodal organs.
  • Although some case reports have been published, clinicopathologic characteristics of multiorgan MALT lymphomas remain unclear.
  • METHODS: The authors evaluated 7 MALT lymphoma cases involving multiorgans in the past 7 years.
  • In this period, they experienced 304 cases of MALT lymphomas.
  • The patients were rather resistant to the various therapeutic approaches.
  • CONCLUSIONS: Multiorgan MALT lymphomas are rather rare.
  • Most cases probably derived from a single clone, and lymphoma cells may selectively move among MALTs via a homing system with preferential involvement of the colon.
  • Because multiorgan MALT lymphomas rarely achieve complete remission by treatment with combination chemotherapy or irradiation, MALT lymphomatous lesions should be checked carefully, especially in the large intestine.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Base Sequence. Fatal Outcome. Female. Gene Rearrangement. Humans. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Male. Middle Aged. Molecular Sequence Data. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180081.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Dohden K, Kaizaki Y, Hosokawa O, Hayashi H, Hattori M: Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report of a case. Dis Colon Rectum; 2004 Sep;47(9):1544-6
Hazardous Substances Data Bank. Ofloxacin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report of a case.
  • PURPOSE: Several articles have reported regression of rectal lymphoma of mucosa-associated lymphoid tissue after anti- Helicobacter pylori therapy.
  • It remains unclear, however, whether lymphoma of rectal mucosa-associated lymphoid tissue is related to Helicobacter pylori infection.
  • Pathologic diagnosis of a biopsy specimen was low-grade mucosa-associated lymphoid tissue lymphoma.
  • The patient received a ten-day course of levofloxacin, and the cycle was repeated three times over seven months.
  • CONCLUSION: Our findings in this case suggest that rectal lymphoma of mucosa-associated lymphoid tissue may be related to unknown microorganisms other than Helicobacter pylori.
  • Levofloxacin may be effective for treatment of rectal lymphoma of mucosa-associated lymphoid tissue regardless of Helicobacter pylori infection.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Helicobacter Infections / drug therapy. Helicobacter pylori / pathogenicity. Intestinal Mucosa / pathology. Levofloxacin. Lymphoma / drug therapy. Lymphoma / microbiology. Ofloxacin / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / microbiology
  • [MeSH-minor] Female. Gastrointestinal Hemorrhage / etiology. Humans. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. Levofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486755.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 6GNT3Y5LMF / Levofloxacin; A4P49JAZ9H / Ofloxacin
  •  go-up   go-down


11. Hisabe T, Imamura K, Furukawa K, Tsuda S, Matsui T, Yao T, Kanda M, Ohshima K, Kikuchi M: Regression of CD5-positive and Helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma of the rectum after administration of antibiotics: report of a case. Dis Colon Rectum; 2002 Sep;45(9):1267-70
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of CD5-positive and Helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma of the rectum after administration of antibiotics: report of a case.
  • We report a case of mucosa-associated lymphoid tissue lymphoma of the rectum that regressed after antibiotics administration.
  • Colonoscopy performed in July 1998 showed a hemispheric protrusion of the rectum, the surface of which was covered with normal rectal mucosa.
  • Pathologic diagnosis of a biopsy specimen was low-grade mucosa-associated lymphoid tissue lymphoma.
  • Repeat colonoscopy ten days after initiation of treatment showed that the rectal tumor had disappeared, and this was confirmed by histologic examination.
  • [MeSH-major] Amoxicillin / therapeutic use. Anti-Bacterial Agents / therapeutic use. Clarithromycin / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Omeprazole / analogs & derivatives. Omeprazole / therapeutic use. Penicillins / therapeutic use. Rectal Neoplasms / drug therapy
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Aged. Antigens, CD5 / analysis. Colonoscopy. Drug Therapy, Combination. Female. Helicobacter pylori. Humans. Lansoprazole

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352248.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Bacterial Agents; 0 / Antigens, CD5; 0 / Penicillins; 0K5C5T2QPG / Lansoprazole; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  •  go-up   go-down


12. Takada M, Ichihara T, Fukumoto S, Nomura H, Kuroda Y: Laparoscopy-assisted colon resection for mucosa-associated lymphoid tissue (MALT) lymphoma in the cecum. Hepatogastroenterology; 2003 Jul-Aug;50(52):1003-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy-assisted colon resection for mucosa-associated lymphoid tissue (MALT) lymphoma in the cecum.
  • Colonic MALToma (mucosa-associated lymphoid tissue lymphoma) has not been well investigated compared to stomach MALToma which is related to Helicobacter pylori infection.
  • We report the uncommon case of MALToma in the cecum initially identified as submucosal tumor, successfully treated by laparoscopy-assisted resection with systemic lymphadectomy.
  • As the metastatic ability and sensitivity against chemotherapy of colonic MALToma is not known, temporally, this treatment seems to be the best choice.
  • [MeSH-major] Cecal Neoplasms / surgery. Lymphoma, B-Cell, Marginal Zone / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12845967.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Nomura E, Uchimi K, Abue M, Kon H, Noguchi T, Suzuki S, Suzuki M, Onodera H, Tateno H, Ota Y: [Regression of MALT lymphoma of the rectum after Helicobacter pylori eradication therapy in a patient negative for Helicobacter pylori]. Nihon Shokakibyo Gakkai Zasshi; 2010 Sep;107(9):1466-73
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of MALT lymphoma of the rectum after Helicobacter pylori eradication therapy in a patient negative for Helicobacter pylori].
  • Colonoscopy revealed a submucosal tumor in the rectum (Ra) and a diagnosis of MALT lymphoma was made on the histological examination of the biopsy specimens and Southern blot analysis of the immunoglobulin heavy chain gene rearrangement.
  • Although the patient was negative for Helicobacter pylori, H. pylori eradication therapy was performed.
  • Colonoscopy 3 months after the eradication therapy showed disappearance of the rectal tumor. H. pylori eradication appears to be a useful treatment for not only H. pylori-positive colonic MALT lymphoma but H. pylori-negative colonic MALT lymphoma.
  • [MeSH-major] Anti-Infective Agents / administration & dosage. Lymphoma, B-Cell, Marginal Zone / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage. Amoxicillin / administration & dosage. Anti-Bacterial Agents / administration & dosage. Clarithromycin / administration & dosage. Drug Therapy, Combination. Female. Helicobacter pylori / drug effects. Helicobacter pylori / isolation & purification. Humans. Lansoprazole. Middle Aged

  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20827043.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0K5C5T2QPG / Lansoprazole; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin
  •  go-up   go-down


14. D'Antonio A, Boscaino A, Addesso M, Liguori G, Nappi O: Nonpolypoid intestinal mantle cell lymphoma resembling MALT lymphoma with successful response to rituximab. South Med J; 2008 Nov;101(11):1168-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonpolypoid intestinal mantle cell lymphoma resembling MALT lymphoma with successful response to rituximab.
  • Two unusual cases of mantle cell lymphoma are reported.
  • They involved the ileum and right colon without multiple lymphomatous polyposis and morphologically resembled an extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / physiopathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19088534.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Gan JL, Tang ZJ: [Clinical, endoscopic and pathological features of primary colorectal non-Hodgkin lymphoma: 24 cases report]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Nov;9(6):502-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical, endoscopic and pathological features of primary colorectal non-Hodgkin lymphoma: 24 cases report].
  • OBJECTIVE: To investigate the clinical, endoscopic and pathological features in primary colorectal non-Hodgkin lymphoma.
  • METHODS: Twenty-four cases of primary colorectal non-Hodgkin lymphoma were studied retrospectively.
  • There were 6 cases (25.0%) involving two or more lesion sites, including three cases showing continuous skip-distribution from sigmoid colon to ascending colon, one case showing the homologous manifestation from rectum to cecum, one case involving ascending colon and rectum, and the last one involving sigmoid colon and rectum.
  • The major pathology types were diffuse large B-cell lymphoma (11/24, 45.8%), intestinal T-cell lymphoma (8/24, 33.3%), and mucosa-associated lymphoid tissue lymphoma (MALT) (3/24, 12.5%).
  • Sixteen postoperative patients accepted CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or COP (cyclophosphamide, vincristine, prednisone) chemotherapy, and three patients abandoned treatment.
  • CONCLUSION: The clinical features of primary colorectal non-Hodgkin's lymphoma have no specificity.
  • Diffuse large B-cell lymphoma and intestinal T-cell lymphoma are the main pathological types.
  • Comprehensive treatment of surgery and chemotherapy are effective methods for primary colorectal non-Hodgkin lymphoma.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Endoscopy. Female. Follow-Up Studies. Humans. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143795.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Radman I, Kovacević-Metelko J, Aurer I, Nemet D, Zupancić-Salek S, Bogdanić V, Sertić D, Mrsić M, Pulanić R, Gasparović V, Labar B: Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study. Croat Med J; 2002 Oct;43(5):555-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study.
  • AIM: To evaluate the role of surgical resection in the treatment of patients with primary gastrointestinal non-Hodgkin s lymphoma in our institution.
  • METHOD: The retrospective study included 79 patients with a histologically confirmed primary gastrointestinal lymphoma, who were diagnosed and treated for the disease in the 1978-1997 period.
  • According to the treatment modality, the patients were divided into surgically treated and surgically non-treated group.
  • RESULTS: The stomach was the primary site of non-Hodgkin s lymphoma in 45 (57%) patients, small intestine in 19 (24%), and colon in 9 (11%) patients.
  • Aggressive histology was found in 51 cases (65%), and low grade mucosa-associated lymphoid tissue (MALT) lymphoma in 28 (35%).
  • Helicobacter pylori infection was registered in 20 out of 45 patients with gastric lymphoma.
  • Twenty-six (33%) patients underwent surgical resection followed by chemotherapy, 47 (59%) were treated with chemotherapy alone, and 6 (8%) received antibiotics plus chemotherapy.
  • Patients with gastric lymphoma had better OS and EFS than patients with primary lymphoma at other sites (65% vs 42%, and 62 vs 28%, respectively) (p=0.005).
  • CONCLUSION: Primary gastrointestinal lymphoma can be successfully treated with chemotherapy alone but surgery remains an important therapeutic option for emergency problems.
  • [MeSH-major] Colonic Neoplasms / surgery. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / surgery. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402395.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


17. de Boer JP, Hiddink RF, Raderer M, Antonini N, Aleman BM, Boot H, de Jong D: Dissemination patterns in non-gastric MALT lymphoma. Haematologica; 2008 Feb;93(2):201-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissemination patterns in non-gastric MALT lymphoma.
  • BACKGROUND: In contrast to gastric extranodal marginal zone mucosa associated lymphoid tissue (MALT) lymphomas, there is little consensus on the value and clinical consequences of extensive staging at diagnosis and during follow-up in non-gastric MALT lymphomas.
  • DESIGN AND METHODS: Complete clinical information at presentation and during follow-up was collected for 72 patients with non-gastric MALT lymphoma treated at the Netherlands Cancer Institute between 1977 and 2005.
  • RESULTS: Twenty-three of our patients (32%) had more than one site of extranodal MALT lymphomatous disease, 13 patients (18%) had regional nodal involvement and 7 (10%) had bone marrow involvement.
  • Site-specific dissemination was seen in paired organs (orbit, lung) and in the gastrointestinal tract (stomach, colon) and primary pulmonary MALT lymphoma was specifically related to gastric involvement (p<0.0001).
  • CONCLUSIONS: Primary extranodal non-gastric marginal zone MALT lymphoma frequently presents as stage IV disease (26%) and multifocal disease (32%) and with a site-specific dissemination pattern.
  • After an extensive staging procedure at presentation, we recommend primary site-directed protocols during follow-up focused on the primary involved tract/organ system, regional lymph nodes and pulmonary and gastric relapses.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lung Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autoimmune Diseases / drug therapy. Autoimmune Diseases / pathology. Bone Marrow Neoplasms / drug therapy. Female. Follow-Up Studies. Helicobacter Infections / drug therapy. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223283.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


18. Nakase H, Okazaki K, Ohana M, Ikeda K, Uchida K, Uose S, Itoh T, Iwano M, Watanabe N, Yazumi S, Kawanami C, Inoue F, Chiba T: The possible involvement of micro-organisms other than Helicobacter pylori in the development of rectal MALT lymphoma in H. pylori-negative patients. Endoscopy; 2002 Apr;34(4):343-6
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The possible involvement of micro-organisms other than Helicobacter pylori in the development of rectal MALT lymphoma in H. pylori-negative patients.
  • It remains unclear whether lymphoma of the mucosa-associated lymphoid tissue (MALT) in the extragastric organs is related to Helicobacter pylori infection or not.
  • This report describes three patients with rectal MALT lymphoma negative for H. pylori infection, all of whom showed disease regression after being treated with antibiotics.
  • One patient had MALT lymphoma in both the descending colon and the rectum; the other two patients had rectal disease only.
  • These patients received antibiotic therapy.
  • In all the patients, regression of MALT lymphoma was observed endoscopically and histologically, and polymerase chain reaction revealed that a previously observed rearranged band of immunoglobulin heavy chain had also disappeared after antibiotic treatment.
  • These cases therefore suggest involvement of micro-organisms other than H. pylori in the development of rectal MALT lymphoma.
  • [MeSH-major] Helicobacter Infections / diagnosis. Helicobacter pylori / isolation & purification. Intestinal Mucosa / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents. Biopsy, Needle. Colonoscopy. Drug Therapy, Combination / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11932795.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


19. Ersoz F, Toros AB, Bektas H, Ozcan O, Koc O, Arikan S: MALT lymphoma of the rectum, presenting with rectal prolapsus: a case report. Cases J; 2010;3(1):33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MALT lymphoma of the rectum, presenting with rectal prolapsus: a case report.
  • Up to now, there have been only a few reported cases of Mucosa-associated lymphoid tissue (MALT) lymphomas arising in the rectum.
  • Its clinical presentation is indistinguishable from that of rectal carcinoma but the treatment is apparently different.
  • In this rare case, a female patient admitted to the emergency service with prolapsus of a rectal mass.The optimal treatment of rectal MALT lymphoma is not well defined yet, given the rarity of the disease.
  • Surgical resection of the localized lesion and following adjuvant chemotherapy has proved to be an effective treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Nov;51(11):1719-23 [18633678.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1370-5 [16549831.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2352-4 [10521996.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):514-5 [10465640.001]
  • [Cites] Br J Haematol. 1998 Jan;100(1):3-14 [9450784.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 2:37-9 [9209638.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1624-30 [9193362.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4445-51 [8977236.001]
  • [Cites] Lancet. 1996 Jul 27;348(9022):268-9 [8684218.001]
  • [Cites] Histopathology. 1987 May;11(5):445-62 [3497084.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):677-84 [12079516.001]
  • [Cites] Endoscopy. 2002 Apr;34(4):343-6 [11932795.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B100-5 [11757688.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • (PMID = 20180989.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2828431
  •  go-up   go-down


20. Grünberger B, Wöhrer S, Streubel B, Formanek M, Petkov V, Puespoek A, Haefner M, Hejna M, Jaeger U, Chott A, Raderer M: Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol; 2006 Mar 20;24(9):1370-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma.
  • PURPOSE: Apart from anecdotal reports implicating Helicobacter pylori (HP) in the development of extragastric mucosa associated lymphoid tissue (MALT) lymphoma, no large scale prospective studies have been performed on this topic.
  • PATIENTS AND METHODS: A total of 77 patients with extragastric MALT lymphoma were prospectively studied.
  • Patients were also tested for hepatitis A, B, and C and autoimmune conditions along with assessment of MALT lymphoma-specific genetic changes.
  • All patients with HP-infection underwent eradication, 16 before initiation of further therapy.
  • Apart from one patient with lymphoma involving parotid and colon, who achieved regression of the colonic lesions, none of these 16 patients showed regression of the lymphoma after a median follow-up of 14 months (range, 8 to 48+ months) before initiation of definitive treatment.
  • CONCLUSION: In our series, HP-eradication was ineffective for treatment of extragastric MALT lymphomas.
  • Antibiotic treatment targeting HP should, therefore, be discouraged in patients with extragastric MALT lymphomas.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / microbiology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549831.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


21. Sakai R, Kanamori H, Ishigatsubo Y: [Long-term remission after CHOP therapy in a case of multifocal extranodal diffuse large B-cell lymphoma with t(1 ; 14) (p22 ; q32) and rearrangement of bcl-10]. Rinsho Ketsueki; 2005 Oct;46(10):1105-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term remission after CHOP therapy in a case of multifocal extranodal diffuse large B-cell lymphoma with t(1 ; 14) (p22 ; q32) and rearrangement of bcl-10].
  • q32) has been reported only in cases of mucosa-associated lymphoid tissue (MALT) lymphomas.
  • A recent report indicates a pathogenic role of bcl-10 mutation in the progression of MALT lymphomas.
  • In this report, we describe the first case of multiple extranodal diffuse large B-cell lymphoma (DLBCL) with t(1 ; 14)(p22 ; q32).
  • A 70-year-old woman was diagnosed as having DLBCL of multiple extranodal sites (lung, duodenum, colon and kidney).
  • She achieved complete remission after six cycles of chemotherapy and has been free of disease for more than five years.
  • This is the first case of bcl-10 gene rearrangement in DLBCL with t(1 ; 14)(p22 ;.
  • q32) and this gene may be involved in the pathogenesis of aggressive lymphomas such as MALT lymphomas or in the progression of MALT lymphomas.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Rearrangement. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Translocation, Genetic
  • [MeSH-minor] Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, B-Cell, Marginal Zone / genetics. Prednisolone / administration & dosage. Remission Induction. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440771.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BCL10 protein, human; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


22. Heise W: Gastric lymphomas: aspects of follow-up and after-care. Recent Results Cancer Res; 2000;156:69-77
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The predominant role of infection with Helicobacter pylori in the pathogenesis as a pre-malignant condition of a special lymphoma entity [gastric lymphoma of the mucosa-associated lymphoid tissue (MALT) type], has defined new diagnostic procedures and concepts of treatment.
  • Therefore, prognostic factors (e.g. stage of lymphoma, histopathologic grading, resectability etc.) are extremely important for the intensity and efficacy of follow-up and after-care.
  • Surveillance programs in gastric lymphoma include sequelae of surgical resection, chemotherapy and radiotherapy, and the efficacy of follow-up procedures have to be measured by the prevention of tumor relapse in comparison to the intensity of diagnostic procedures.
  • Since lymphoma relapse may occur both as local or disseminated recurrence in 13%-35% of cases, follow-up procedures have to regard both aspects during surveillance.
  • While these follow-up programs are standardized in epithelial tumors (e.g. colon carcinoma), they are not yet established or comparable for each type of gastric lymphoma.
  • Low-grade MALT lymphomas have to be considered as a new lymphoma entity.
  • In addition, new diagnostic procedures (e.g. molecular parameters such as polymerase chain reaction (PCR) for clonality, endosonography, "gastric mapping") have been found to be important parameters for diagnosis and staging of gastric lymphoma and may therefore be relevant for the course of the disease.
  • The definition of "lymphoma cure" and the impact of these procedures as prognostic factors will have to be discussed and may influence the follow-up of gastric lymphoma.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Combined Modality Therapy. Humans. Prognosis. Radiotherapy / adverse effects. Recurrence. Surgical Procedures, Operative

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10802865.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 26
  •  go-up   go-down


23. Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY: Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol; 2008 May;87(4):375-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine.
  • All cases were reclassified according to the World Health Organization (WHO) classification of lymphoma in 2001.
  • Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients.
  • Twenty-five patients had primary colorectal lymphoma, with B-cell origin accounting for 92.0% and T-cell origin for 8.0% of these patients.
  • The ileocaecal region has the highest involved rate (13 of 25 patients, 52.0%), followed by colon (7 of 25 patients, 28.0%) and rectum (3 of 25 patients, 12.0%).
  • Compared with surgery alone, post-operation chemotherapy or chemoradiotherapy can significantly improve DLBCL patients' event-free survival (EFS).
  • However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma.
  • B-cell lymphoma is the most common pathological type of intestinal lymphomas.
  • Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5 [17143795.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Am Surg. 1988 May;54(5):262-6 [3364860.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Gastroenterol Jpn. 1976;11(2):141-7 [789171.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2243-7 [16416168.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Rofo. 1983 Mar;138(3):283-7 [6403420.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 1988;27(1):51-5 [3284553.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4 [16750023.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Med Oncol. 2006;23(2):225-35 [16720923.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 18409078.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Aleman BM, Haas RL, van der Maazen RW: Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):27-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract.
  • In patients with gastrointestinal lymphoma the most frequently involved site is the stomach (60%-75% of cases), followed by the small bowel, ileum, cecum, colon and rectum.
  • The most common histological subtypes are extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) and diffuse large B-cell lymphoma (DLBCL).
  • The role of radiotherapy is most definite in early stage gastric lymphoma.
  • The therapeutic approach for patients with gastric Non Hodgkin lymphoma (NHL) has changed significantly over the last decades.
  • The primary treatment of limited gastric MALT lymphoma consists of Helicobacter pylori eradication.
  • In patients with gastric DLBCL conservative treatment with anthracycline-based chemotherapy alone or in combination with involved-field radiotherapy has become the therapy of choice.
  • [MeSH-major] Intestinal Neoplasms / radiotherapy. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Radiotherapy, Intensity-Modulated. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Chemotherapy, Adjuvant. Dose Fractionation. Helicobacter pylori / pathogenicity. Humans. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206106.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 46
  •  go-up   go-down


25. Psyrri A, Papageorgiou S, Economopoulos T: Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol; 2008 Dec;19(12):1992-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal lymphoma is the most common form of extranodal lymphoma, accounting for 30%-40% of cases.
  • The most commonly involved site is the stomach (60%-75% of cases), followed by the small bowel, ileum, cecum, colon and rectum.
  • The most common histological subtypes are diffuse large B-cell lymphoma (DLBCL) and marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT).
  • Helicobacter pylori infection has been implicated in the pathogenesis of MALT gastric lymphoma, but its role in gastric diffuse large B-cell non-Hodgkin's lymphoma (NHL) is controversial.
  • The therapeutic approach for patients with gastric NHL has been revised over the last 10 years.
  • Conservative treatment with anthracycline-based chemotherapy alone or in combination with involved-field radiotherapy has replaced gastrectomy as standard therapy in cases with DLBCL.
  • Additionally, MALT lymphomas are mainly treated with antibiotics alone, which can induce lasting remissions in those cases associated with H. pylori infection.
  • Nevertheless, various therapeutic aspects for primary gastric lymphomas are still controversial and several questions remain unanswered.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5061-6 [16051953.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6370-8 [16155022.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6415-20 [16155028.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1345-53 [16174856.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8018-24 [16204012.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8442-6 [16293875.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):721-6 [16556173.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2096-101 [17071482.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2110-4 [17071484.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2140-6 [17071488.001]
  • [Cites] Oncology. 2006;70(6):411-7 [17220639.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):65-71 [17339119.001]
  • [Cites] Gut. 2007 Dec;56(12):1685-7 [17639089.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):895-901 [10705011.001]
  • [Cites] Hematol Oncol. 2000 Mar;18(1):15-9 [10797526.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] J Clin Gastroenterol. 1994 Mar;18(2):99-104 [8189031.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):767-9 [7717599.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Hematol Oncol. 1995 May-Jun;13(3):153-63 [7622145.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):3-11 [8988720.001]
  • [Cites] Histopathology. 1997 May;30(5):425-9 [9181363.001]
  • [Cites] Ann Oncol. 1997 May;8(5):419-21 [9233518.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):979-85 [9402171.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1916-21 [9586910.001]
  • [Cites] Leuk Lymphoma. 1999 May;33(5-6):531-41 [10342580.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Oncogene. 1999 Oct 14;18(42):5785-94 [10523859.001]
  • [Cites] J Pathol. 2005 Jan;205(2):255-74 [15643667.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1979-83 [15668468.001]
  • [Cites] Acta Haematol. 2005;113(2):97-103 [15802887.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Recent Results Cancer Res. 2000;156:99-103 [10802868.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):187-90 [10823136.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):95-102 [11145257.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1600-9 [11250988.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2041-8 [11283137.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1182-7 [11493468.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4245-51 [11709568.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B100-5 [11757688.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1094-8 [12176789.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1120-7 [12176793.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • [Cites] Blood. 2003 May 15;101(10):3875-6 [12531812.001]
  • [Cites] Gut. 2003 Jun;52(6):912-3 [12740354.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):11-6 [14695844.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1086-90 [15205203.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Oncology. 2004;66(6):476-80 [15452377.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):391-7 [3840030.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1153-64 [2349966.001]
  • [Cites] Eur J Cancer. 1990;26(7):855 [2145918.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Gastroenterology. 1991 Nov;101(5):1159-70 [1936785.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Histopathology. 1992 Jan;20(1):29-34 [1737623.001]
  • [Cites] Lancet. 1992 Apr 4;339(8797):834-5 [1347858.001]
  • [Cites] Histopathology. 1992 Nov;21(5):415-21 [1452124.001]
  • [Cites] Oncology. 1992;49(6):484-8 [1465289.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • (PMID = 18647965.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2733120
  •  go-up   go-down


26. Auner HW, Beham-Schmid C, Lindner G, Fickert P, Linkesch W, Sill H: Successful nonsurgical treatment of primary mucosa-associated lymphoid tissue lymphoma of colon presenting with multiple polypoid lesions. Am J Gastroenterol; 2000 Sep;95(9):2387-9
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful nonsurgical treatment of primary mucosa-associated lymphoid tissue lymphoma of colon presenting with multiple polypoid lesions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Polyps / diagnosis. Lymphoma, B-Cell, Marginal Zone / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11007252.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Yamada M, Kawahara H, Shiroeda H, Tsuchishima M, Masaki Y, Sato K, Takase S: Successful rituximab monotherapy for API2-MALT1 fusion positive primary mucosa-associated lymphoid tissue lymphoma of the transverse colon in a patient with liver cirrhosis. Scand J Gastroenterol; 2008;43(6):761-4
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful rituximab monotherapy for API2-MALT1 fusion positive primary mucosa-associated lymphoid tissue lymphoma of the transverse colon in a patient with liver cirrhosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Liver Cirrhosis / complications. Lymphoma, B-Cell, Marginal Zone / drug therapy. Oncogene Proteins, Fusion / analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569996.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / API2-MALT1 fusion protein, human; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Oncogene Proteins, Fusion; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down






Advertisement